AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTAbbott entered into an Agreement and Plan of Merger on November 19, 2025 with Exact Sciences Corporation and its subsidiary Badger Merger Sub I, Inc., pursuant to which each of Exact Sciences' issued and outstanding common shares will be converted at the effective time into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes.
Key points
AI summaryAbbott entered into an Agreement and Plan of Merger on November 19, 2025 with Exact Sciences Corporation and its subsidiary Badger Merger Sub I, Inc., pursuant to which each of Exact Sciences' issued and outstanding common shares will be converted at the effective time into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes.
Abbott said the acquisition of all outstanding shares of Exact Sciences for $105 per common share represents a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion, with its financing contemplating absorption of Exact Sciences' estimated $1.8 billion of net debt.
Abbott said the closing is expected in Q2 2026 and is subject to Exact Sciences shareholder approval, expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and receipt of applicable regulatory approvals.
Abbott said it entered into a commitment letter on November 19, 2025 with Morgan Stanley Senior Funding, Inc., pursuant to which the commitment party committed to provide, subject to the terms and conditions of the commitment letter, up to $20,000,000,000 of senior unsecured bridge loans.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Merger Agreement for Acquisition of Exact Sciences at $105.00 Per Share in Cash
Abbott entered into an Agreement and Plan of Merger on November 19, 2025 with Exact Sciences Corporation and its subsidiary Badger Merger Sub I, Inc., pursuant to which each of Exact Sciences' issued and outstanding common shares will be converted at the effective time into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes.
Source · Based on the filing body and exhibits
Acquisition Equity Value of Approximately $21 billion and Net Debt of $1.8 billion
Abbott said the acquisition of all outstanding shares of Exact Sciences for $105 per common share represents a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion, with its financing contemplating absorption of Exact Sciences' estimated $1.8 billion of net debt.
Source · Based on the filing body and exhibits
Closing Conditions and Expected Closing in Q2 2026
Abbott said the closing is expected in Q2 2026 and is subject to Exact Sciences shareholder approval, expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and receipt of applicable regulatory approvals.
Source · Based on the filing body and exhibits
Morgan Stanley $20,000,000,000 Bridge Loan Commitment
Abbott said it entered into a commitment letter on November 19, 2025 with Morgan Stanley Senior Funding, Inc., pursuant to which the commitment party committed to provide, subject to the terms and conditions of the commitment letter, up to $20,000,000,000 of senior unsecured bridge loans.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…